Clinical trials: Pharmacotherapy
Stomach Neoplasm
Randomized Multicenter Study Comparing Docetaxel Plus Cisplatin and 5-FU to Cisplatin Plus 5-FU in Advanced Gastric Cancer
Phase II: Primary objective: to select one of the 2 test arms (docetaxel with cisplatin, docetaxel with cisplatin and 5-FU), based primarily on complete responses, to advance to a phase III survival comparison against the CDDP +…
- Trial name
- NCT00290966
- Testing
- XRP6976
- Volunteers
- 610 people
- Sponsor
- Sanofi
Lung Cancer, Pulmonary Neoplasms
Evaluation of the Overall Survival of Meclinertant Versus Placebo After a First Line Chemotherapy With Cisplatin + Etoposide
To demonstrate an increase in overall survival for patients with newly diagnosed extended stage small cell lung cancer when treated with SR48692 versus placebo, after an initial response (complete or partial response or stable)…
- Conditions
- Lung Cancer, Pulmonary Neoplasms, Small Cell Lung Cancer
- Trial name
- SESAME (NCT00290953)
- Testing
- SR48692
- Where
- 14 sites in Argentina, Australia and 12 more
- Volunteers
- 432 people
- Sponsor
- Sanofi
Tumors
A Safety and Efficacy Study of Carboplatin, Paclitaxel, Bevacizumab and CA4P in Non-Small Cell Lung Cancer
The purpose of this study is to determine the safety, tolerability and efficacy of combretastatin A4 phosphate (CA4P), also known as fosbretabulin, in combination with bevacizumab (Avastin), carboplatin and paclitaxel in patients…
- Trial name
- FALCON (NCT00653939)
- Testing
- Fosbretabulin, Carboplatin, Paclitaxel
- Where
- 15 sites in United States
- Volunteers
- 63 people
- Sponsor
- Mateon Therapeutics
Non Squamous Non Small Cell Lung Cancer
A Study to Compare Effects and Safety of CT-P51 and Keytruda in Patients With Previously Untreated Metastatic Lung Cancer
The goal of this Phase 3 clinical trial is to compare efficacy and safety of CT-P51 and European Union (EU) approved Keytruda in combination with platinum pemetrexed chemotherapy in patients with previously untreated metastatic…
- Trial name
- NCT06939595
- Testing
- CT-P51, EU-approved Keytruda
- Where
- Georgia
- Volunteers
- 225 people
- Sponsor
- Celltrion
Inborn Errors of Metabolism
Induced Pluripotent Stem Cells for the Development of Novel Drug Therapies for Inborn Errors of Metabolism (iPSC-IEM)
Human induced pluripotent stem cells (iPSCs), are reprogrammed from somatic cells that can self-renew indefinitely and produce different types of cells. They provide human model cell lines for orphan drug development.
- Trial name
- iPSC-IEM (NCT04097275)
- Testing
- Skin biopsy, Withdraw of blood
- Where
- Pakistan
- Volunteers
- 1,000 people
- Sponsor
- CENTOGENE GmbH Rostock
Melanoma
A Comparative Study in Chinese Subjects With Chemotherapy Naïve Stage IV Melanoma Receiving Ipilimumab (3 mg/kg) vs. Dacarbazine
The purpose of this study is to determine whether Ipilimumab will extend the life of chinese patients with Chemotherapy Naive Stage IV Melanoma more than Dacarbazine as well as to examine safety in this patient population.
- Trial name
- NCT02545075
- Testing
- Ipilimumab, Dacarbazine
- Where
- 8 sites in China
- Volunteers
- 182 people
- Sponsor
- Bristol-Myers Squibb
Squamous Non Small Cell Lung Cancer
A Randomized, Double-blind, Placebo Controlled Phase III Study to Investigate Efficacy and Safety of First-Line Treatment With HLX10 + Chemotherapy (Carboplatin-Nanoparticle Albumin Bound (Nab) Paclitaxel) in Patients With Stage IIIB/IIIC or IV NSCLC
This study is a randomized, double-blind, multicenter, phase III clinical study to compare the clinical efficacy and safety of HLX10 + chemotherapy vs chemotherapy in subjects with locally advanced or metastatic squamous NSCLC…
- Trial name
- NCT04033354
- Testing
- HLX10, carboplatin and nab paclitaxel
- Where
- 92 sites in United States, China and 5 more
- Volunteers
- 537 people
- Sponsor
- Shanghai Henlius Biotech
Diffuse Large B-Cell Lymphoma
Avelumab In Combination Regimens That Include An Immune Agonist, Epigenetic Modulator, CD20 Antagonist and/or Conventional Chemotherapy in Patients With Relapsed or Refractory Diffuse Large B-cell Lymphoma (R/R DLBCL)
Study B9991011 is a multi-center, international, randomized, open label, 2 component (Phase 1b followed by Phase 3), parallel-arm study of avelumab in combination with various agents for the treatment of Relapsed/Refractory (R/R)…
- Trial name
- Javelin DLBCL (NCT02951156)
- Testing
- Avelumab, Utomilumab, Rituximab
- Where
- 29 sites in United States, Australia and 6 more
- Volunteers
- 29 people
- Sponsor
- Pfizer
Healthy Volunteers
A Study of TAK-881 With and Without Ramp-Up Dosing in Healthy Adults
The main aim of this study is to check how well healthy adults can tolerate TAK-881 with different dosing schedules. During the study, participants will receive one infusion of TAK-881 under the skin (subcutaneous [SC] infusion)…
- Trial name
- NCT06935266
- Testing
- TAK-881, SC Investigational Needle Sets
- Where
- United States
- Volunteers
- 64 people, healthy volunteers welcome
- Sponsor
- Takeda
Helicobacter Pylori
A Study of Vonoprazan in Adults With Helicobacter Pylori
Helicobacter Pylori (H Pylori) is a bug found in the digestive system. It can cause soreness and redness in the stomach (gastritis). It can also cause ulcers in the stomach and other parts of the digestive system.
- Trial name
- NCT04753437
- Testing
- Clarithromycin, Amoxicillin, Bismuth potassium citrate
- Where
- China
- Volunteers
- 44 people
- Sponsor
- Takeda
Non-Squamous Non-Small Cell Lung Cancer
A Study of Onartuzumab (MetMAb) in Combination With Tarceva (Erlotinib) in Participants With Met Diagnostic-Positive Non-Small Cell Lung Cancer Who Have Received Chemotherapy For Advanced or Metastatic Disease (MetLung)
This randomized, multicenter, double-blind, placebo-controlled study will evaluate the efficacy and safety of onartuzumab (MetMAb) in combination with Tarceva (erlotinib) in participants with incurable non-small cell lung cancer…
- Trial name
- NCT01456325
- Testing
- Erlotinib, Onartuzumab (MetMab)
- Where
- 213 sites in United States, Argentina and 25 more
- Volunteers
- 494 people
- Sponsor
- Genentech, Inc.
RAS/BRAF Wild Type Colorectal Cancer
TQB2922 and TAS-102 Tablets for Injection With or Without Bevacizumab in Chemotherapy-failed RAS/BRAF Wild-type Advanced Colorectal Cancer
This is a multicenter, open Phase Ib/II clinical study evaluating the safety and efficacy of TQB2922 in combination with TAS-102±bevacizumab in subjects with RAS/BRAF wild-type unresectable locally advanced or metastatic…
- Trial name
- NCT07044908
- Testing
- TQB2922 injection ± TAS-102 tablets, TQB2922 injection+TAS-102 tablets ± Bevacizumab
- Where
- 27 sites in China
- Volunteers
- 72 people
- Sponsor
- Chia Tai Tianqing Pharmaceutical Group Nanjing Shunxin Pharmaceutical Co., Ltd.
Cervical Cancer
JSKN033 Combination Therapy in Subjects With Advanced Cervical Cancer
The goal of this clinical trial is to learn if the therapy of JSKN033 plus chemotherapy with or with bevacizumab is safe to treat patients with advanced cervical cancer.
- Trial name
- NCT07497074
- Testing
- JSKN033, Platinum, Bevacizumab
- Where
- 2 sites in China
- Volunteers
- 78 people
- Sponsor
- Jiangsu Alphamab Biopharmaceuticals Co., Ltd
Relapsed and/or Refractory Multiple Myeloma (RRMM)
A Study Of TAK-981 Given With Monoclonal Antibodies (mAbs) In Adults With Relapsed or Refractory Multiple Myeloma (RRMM)
TAK-981 is being tested in combination with anti-CD38 monoclonal antibodies (mAbs) to treat participants who have relapsed or refractory multiple myeloma (RRMM).
- Trial name
- NCT04776018
- Testing
- TAK-981, Mezagitamab, Daratumumab and Hyaluronidase-fihj
- Where
- 13 sites in United States, Canada
- Volunteers
- 27 people
- Sponsor
- Takeda
HIV Infections
Study of a New Protease Inhibitor, BMS-232632, in Combination With Other Anti-HIV Drugs
The purpose of this study is to evaluate a new protease inhibitor known as BMS-232632. This drug will be given in combination with 2 other anti-HIV drugs (stavudine and didanosine).
- Trial name
- NCT00002240
- Testing
- Atazanavir, Nelfinavir mesylate, Stavudine
- Where
- 17 sites in United States, Canada
- Sponsor
- Bristol-Myers Squibb
Ketamine-Induced Brain Activity Changes, Psychotic-like Symptoms
Effects of TAK-063 on Preventing Ketamine-Induced Brain Activity Changes as Well as Psychotic-Like Symptoms in Healthy Male Adults
The purpose of this study is to determine whether ketamine-induced brain activity changes are modulated by TAK-063 administration using neuroimaging battery tests.
- Trial name
- NCT01892189
- Testing
- Ketamine, TAK-063
- Where
- United States
- Volunteers
- 27 people, healthy volunteers welcome
- Sponsor
- Takeda
Ulcerative Colitis and Crohn's Disease
Entyvio (Vedolizumab) Long Term Safety Study
The purpose of this study is to assess the long-term safety of vedolizumab versus other biologic agents in participants with Ulcerative Colitis (UC) or Crohn's Disease (CD).
- Trial name
- Entyvio PASS (NCT02674308)
- Testing
- Vedolizumab, Other Biologic Agents
- Where
- 287 sites in United States, Austria and 19 more
- Volunteers
- 5,302 people
- Sponsor
- Takeda
Carcinoma, Ovarian Epithelial, Ovarian Neoplasms
Oregovomab Plus Chemo in Newly Diagnosed Patients With Advanced Epithelial Ovarian Cancer Following Optimal Debulking Surgery
Study to compare the safety and efficacy of oregovomab versus placebo, administered in combination with specific cycles of a standard six-cycle chemotherapy regimen (paclitaxel and carboplatin), for the treatment of subjects with…
- Conditions
- Carcinoma, Ovarian Epithelial, Ovarian Neoplasms, Ovarian Cancer, Ovarian Serous Adenocarcinoma
- Trial name
- FLORA-5 (NCT04498117)
- Testing
- Oregovomab, Paclitaxel, Carboplatin
- Where
- 148 sites in United States, Argentina and 12 more
- Volunteers
- 615 people
- Sponsor
- CanariaBio Inc.
Lymphoma, Large-Cell, Diffuse
Ofatumumab Versus Rituximab Salvage Chemoimmunotherapy Followed by Autologous Stem Cell Transplant in Relapsed or Refractory Diffuse Large B Cell Lymphoma
This study is being conducted to compare the efficacy and safety of ofatumumab in addition to salvage chemotherapy versus rituximab in addition to salvage chemotherapy in CD20 positive DLBCL subjects relapsing, or with persistent…
- Trial name
- ORCHARRD (NCT01014208)
- Testing
- OFATUMUMAB + DHAP, RITUXIMAB + DHAP
- Where
- 173 sites in United States, Argentina and 24 more
- Volunteers
- 447 people
- Sponsor
- GlaxoSmithKline
Diabetes Mellitus, Type 2
An Observational Study of Patient Cohorts Who Previously Received Long-term Treatment With Pioglitazone or Placebo in Addition to Existing Antidiabetic Medications
The purpose of this study was to investigate the mortality and macrovascular morbidity as well as the incidence of malignancies over time, in high-risk diabetic participants who previously received long-term treatment with either…
- Trial name
- NCT02678676
- Testing
- No Intervention
- Volunteers
- 3,599 people
- Sponsor
- Takeda
The first 1,020 results can be paged through. Add a filter or change the sort order to reach the rest.